16 February 2018 - Both reports will be subject of September Midwest CEPAC meeting; open Input now being accepted until 7 March 2018.

The ICER will assess the comparative clinical effectiveness and value of therapies for high-risk prostate cancer and hereditary amyloidosis in upcoming reports. Both reports are set to be reviewed during a public meeting of the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC) in September of 2018.

The review of prostate cancer treatments is expected to assess the clinical effectiveness and value of three anti-androgen drugs: enzalutamide (Xtandi, Astellas and Medivation), approved by the FDA in 2012, abiraterone acetate (Zytiga, Janssen), first approved in 2011, and apalutamide (Erleada, Janssen), just approved earlier this week.

Read ICER announcement